CDK
Los inhibidores de las quinasas dependientes de ciclina (CDK) son compuestos que bloquean la actividad de las CDK, un grupo de quinasas de proteínas que regulan el ciclo celular, la transcripción y otros procesos celulares. Las CDK se activan al unirse a las ciclinas, y su actividad es crucial para la progresión de las células a través de las diferentes fases del ciclo celular. Inhibir las CDK puede detener la división celular, provocando la detención del ciclo celular y la apoptosis, especialmente en células cancerosas donde las CDK a menudo están desreguladas. Los inhibidores de CDK se utilizan ampliamente en la investigación del cáncer y tienen un potencial terapéutico en el tratamiento de varios tipos de cáncer. En CymitQuimica, ofrecemos una selección completa de inhibidores de CDK de alta calidad para apoyar su investigación en el control del ciclo celular, el cáncer y el desarrollo terapéutico.
Se han encontrado 500 productos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Debio-0123
CAS:<p>Debio-0123: potent, specific oral WEE1 inhibitor; IC50 in low nanomolar; boosts DNA damage & Carboplatin's anti-cancer effects.</p>Fórmula:C26H28Cl2N6OPureza:99.93%Forma y color:SolidPeso molecular:511.45AZD4573
CAS:<p>AZD4573 is an effective and selective CDK9 inhibitor (IC50: <4 nM). It enables transient target engagement for the treatment of hematologic malignancies.</p>Fórmula:C22H28ClN5O2Pureza:99% - 99.51%Forma y color:SolidPeso molecular:429.94PPA-037
CAS:<p>PPA-037 is an orally active and highly selective inhibitor of cyclin-dependent kinase 12 (CDK12). It induces the degradation of Cyclin K, thereby enhancing antiproliferative effects on tumor cells. PPA-037 holds potential for use in cancer research.</p>Fórmula:C25H27N7Forma y color:SolidPeso molecular:425.53CDK1-IN-7
CAS:<p>CDK1-IN-7 (compound M7) is a potent CDK1 inhibitor. It effectively suppresses the proliferation and migration of HCT116 and Lovo cells, making it a valuable tool for colorectal cancer research.</p>Fórmula:C23H19ClN4O3Forma y color:SolidPeso molecular:434.88YL-1-9
CAS:<p>YL-1-9 is an inhibitor that prevents the degradation of p53 by MDM2 through tight binding to the crucial hydrophobic pocket of MDM2. It can induce cell cycle arrest and apoptosis in breast cancer cells [1].</p>Fórmula:C22H23F3N2O3Forma y color:SolidPeso molecular:420.425CDK9 autophagic degrader 1
CAS:<p>CDK9 autophagic degrader 1 (Compound 28) is an ATTEC degrader used to target and degrade CDK9, also impacting the levels of its associated Cyclin T1. At a concentration of 100 nM, it exhibits over 80% inhibition of CDK9.</p>Fórmula:C34H39N7O4S2Forma y color:SolidPeso molecular:673.848CDK9-IN-11
CAS:<p>CDK9-IN-11 is a potent CDK9 inhibitor that is the ligand for the PROTAC CDK9 Degrader-1 [1].</p>Fórmula:C20H25N3O4Pureza:98%Forma y color:SolidPeso molecular:371.43RGB-286638
CAS:<p>RGB-286638 inhibits multiple CDKs and GSK-3β, TAK1, Jak2, MEK1 with IC50s as low as 1-54 nM.</p>Fórmula:C29H37Cl2N7O4Forma y color:SolidPeso molecular:618.55Cimpuciclib tosylate
CAS:<p>Cimpuciclib tosylate, a selective CDK4 inhibitor (IC50: 0.49 nM), exhibits anti-tumor activity.</p>Fórmula:C37H43FN8O4SForma y color:SolidPeso molecular:714.85CDK2/4-IN-2
CAS:<p>CDK2/4-IN-2 (compound 56) serves as a dual inhibitor for CDK2 and CDK4, exhibiting an IC50 of less than 100 nM. It is applicable in cancer research.</p>Fórmula:C18H20F3N7O3S2Forma y color:SolidPeso molecular:503.52CDK2 degrader 4
CAS:<p>CDK2 degrader4 (compound 104) is a potent degrader of CDK2, showing promise for cancer research applications.</p>Fórmula:C23H26ClN3O5Forma y color:SolidPeso molecular:459.923CDK8-IN-9
<p>CDK8-IN-9, potent CDK8 inhibitor (IC50: 48.6 nM), curbs tumor growth, useful for colorectal cancer research.</p>Forma y color:SolidPROTAC CDK12/13 Degrader-1
<p>PROTAC CDK12/13 Degrader-1 (7f) selectively degrades CDK12/13 at nanomolar potency, targeting breast cancer.</p>Forma y color:SolidCDK7-IN-33
CAS:<p>CDK7-IN-33 (Compound 148) is a CDK7 inhibitor with a Ki value of 21.75 nM. It suppresses the proliferation of A549 cells expressing CDK7WT, with a pIC50 of 7.37.</p>Fórmula:C29H36N6O4SForma y color:SolidPeso molecular:564.699CDK/HDAC-IN-1
<p>CDK/HDAC-IN-1 inhibits CDK2/4/6 & HDAC6 with IC50s: 60.9, 276, 27.2, and 128.6 nM respectively.</p>Fórmula:C20H18N4O4Forma y color:SolidPeso molecular:378.38LZ9
CAS:<p>LZ9 is an ATP-competitive inhibitor of CDK1 and CDK2, with potential applications in colorectal cancer (CRC) research.</p>Fórmula:C17H11F3N4O2Forma y color:SolidPeso molecular:360.29CDK1-IN-3
<p>CDK1-IN-3 is a selective inhibitor targeting CDK1 (36.8 nM), CDK2 (305.17 nM), CDK5 (369.37 nM); used in cancer research.</p>Fórmula:C28H25ClF3N5O2Forma y color:SolidPeso molecular:555.98Haspin-IN-2
CAS:<p>Haspin-IN-2 is a potent haspin inhibitor (IC50: 50 nM) and also inhibits CLK1 (IC50: 445 nM) and DYRK1A (IC50: 917 nM).</p>Fórmula:C12H8N4O3Forma y color:SolidPeso molecular:256.22CDK4-IN-1
CAS:<p>CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50</p>Fórmula:C22H29ClN8Pureza:98%Forma y color:SolidPeso molecular:440.97Cdc7-IN-10
CAS:<p>Cdc7-IN-10 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in studies of proliferative diseases.</p>Fórmula:C20H22F2N4O2SForma y color:SolidPeso molecular:420.48
